Protein Kinase C inhibitors in the treatment of diabetic retinopathy. Review

Current Pharmaceutical Biotechnology

Volumn 12, Issue 3, 2011, Pages 386-391

  Gálvez, M I López ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Blood flow; Diabetic macular edema; Diabetic retinopathy; Dyacilglycerol; Midosistaurin; Protein kinasa; Ruboxistaurin; Vascular endothelial growth factor

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; BISINDOLYLMALEIMIDE; MIDOSTAURIN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; ROTTLERIN; RUBOXISTAURIN;

ANOREXIA; ARTICLE; BLOOD FLOW; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIARRHEA; DRUG INHIBITION; ENZYME ACTIVATION; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERGLYCEMIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DISEASE; LASER COAGULATION; LIVER TOXICITY; NAUSEA AND VOMITING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); VISUAL ACUITY; VISUAL IMPAIRMENT; VOMITING;

CLINICAL TRIALS AS TOPIC; DIABETIC RETINOPATHY; HUMANS; HYPERGLYCEMIA; MACULAR EDEMA; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS;

EID: 79551678495     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111794480606     Document Type: Article

References (44)

1. Ciulla, T.A.; Amador, A.G.; Zinman, B. Diabetic retinopathy and diabetic macular edema, pathophysiology, screening, and novel therapies. Diabetes Care, 2003, 26 (9), 2653-2664.
2. Wilkinson, C.P.; Ferris, F.L.; Klein, R.E.; Lee, P.P.; Agardh, C.D.; Davis, M.; Dills, D.; Kampik, A.; Pararajasegaram, R.; Verdaguer, J.T.; Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macu-lar edema disease severity scales. Ophthalmology, 2003, 110, 1677-1682.
3. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med., 1993, 329, 977-986.
4. Early Treatment Diabetic Retinopathy Study Research Group, Early photocoagulation for diabetic retinopathy, ETDRS Report No 9. Ophthalmology, 1991, 98 (Suppl.), 766-785.
5. Grading diabetic retinopathy from stereoscopic color fund us photographs- an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology, 1991, 98, 786.
6. Ferris, F.L.; Patz, A. Macular edema. A complication of diabetic retinopathy. Surv. Ophthalmol, 1984, 28(Suppl), 452-461.
7. Singh, A.; Stewart, J.M. Pathophysiology of diabetic macular edema. Int. Ophthalmol. Clin., 2009, 49, 1-11.
8. Aiello, L.L.P. Perspectives on diabetic retinopathy. Am. J. Ophthalmol, 2003, 136(6), 122-135.
9. American Diabetes Association. Implications of the United Kingdom Propesctive. Diabetes Study. Position Statement. Diabetes Care, 2002, 25, 28-32.
10. Klein, R.; Klein B. E.; Moss, S.E. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann. Intern. Med., 1996, 124, 90.
11. Ferris, F.L 3rd. How effective are treatments for diabetic retinopathy? JAMA, 1993, 269, 1290-1291.
12. Ferris, F.L.; Davis, M.D.; Aiello, L.M. Treatment of diabetic retinopathy. N. Engl. J. Med., 1999, 341, 667-678.
13. Frank, R.N. Potential new medical therapies for diabetic retinopathy, protein kinase C inhibitors. Am. J. Ophthalmol, 2002, 133, 693-698.
14. Aiello, L.L.P. The potential role of PKC in diabetic retinopathy and macular edema. Surv. Ophthalmol, 2002, 47, 263-269.
15. Ways, D.K.; Sheetz, M. J. The role of protein kinase C in the development of the complications of diabetes. Vitam. Horm., 2000, 60, 149-193.
16. Xia, P.; Inoguchi, T.; Kern, T.S.; Engerman, R.L.; Oates, P.J.; King, L. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes, 1994, 43, 1122-1129.
17. Inoguchi, T.; Xia, P.; Kunisaki, M.; Higashi, S.; Feener, E.P.; King, L. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am. J. Physiol., 1994, 267, E369-379.
18. Koya, D.; King, G. Protein kinase C Activation and the development of diabetic complications. Diabetes, 1998, 47, 859-866.
19. Park, J.Y.; Ha, S.W.; King, G. The role of protein kinase C activation in the pathogenesis of diabetic vascular complications. Perit. Dial. Intern., 1999, 19(Suppl 2). S222-227.
20. Takagi, C; Bursell, S.E.; Lin, Y.W.; Takagu, H.; Duh, E.; Jiang, Z.; Clermont, A.C.; King, G.L. Regulation of retinal haemodynam-ics in diabetic rats by increased expression and action of endo-thelin-1. Invest. Ophthalmol. Vis. Sci., 1996, 37, 2504-2518.
21. Donnelly, R.; Idris, I.; Forrester, J.V. Protein Kinase C inhibition and diabetic retinopathy, a shot in the dark at transalational research. Br. Ophthalmol, 2004, 88, 146-151.
22. Mellor, H.; Parker, P. J. The extended protein kinase C superfamily. Biochem. J., 1998, 332, 281-292.
23. Kowluru, R.A. Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol, 2001, 38,179-185.
24. Aiello, L. P.; Bursell, S. E.; Clermont, A.; Duh, E.; Ishii, H.; Takagi, G.; Mori, F.; Ciulla, T.A.; Ways, K.; Jirosuek, M.; Smith, L. E.; King, G.L. Vascular endothelial growth factor-induced retinal permeability is mediatedby protein kinase C in vivo and suppressed by an orally effective p-isoform selective inhbitor. Diabetes, 1997, 46, 1473-1480.
25. Xia, P.; Aiello, L.; Ishii, H.; Jiang, Z.Y.; Park, D.J.; Robinson, G.S.; Takagi, H.; Newsome, W. P.; Jirosuek, M.R.; King, G.L. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms and endothelial cell growth. J. Clin. Invest., 1996, 98, 2018-2026.
26. Suzama, K.; Takahara, N.; Suzuma, I.; IsshiKi, K.; Veki, K.; Leit-ges, M.; Aiello, L. P.; King, G.L. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation and retinal neovascularization. Proc. Natl. Acad. Sci. USA, 2002, 99, 721-726.
27. Bursell, S-E.; King, G.L. Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications? Diab. Res. Clin. Pract., 1999, 45,169-182.
28. Wenberg, L.A. Proximal signaling molecules as potential targets for antiinflammatory theraphy. Curr. Opin. Drug Discov. Dev., 2007, 10, 560-564.
29. Idris, I.; Gray, S.; Donnelly, R. Protein kinase C activation, isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia, 2001, 44, 659-673.
30. Meyer, T.; Regenass, U.; Fabbro, D.; Alteri, E.; Rösel, J.; Muller, M.; Caravatti, G.; Matter, A. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo antitumor activity. Int. J. Cancer, 1989, 43, 851-856.
31. Comer, G.M.; Ciulla, T.A. Pharmacotherapy for diabetic retinopathy. Ocular manifestations of systemic disease. Curr. Opin. Ophthalmol, 2005, 15(6), 508-518.
32. Propper, D.J.; McDonald, A.; Man, P.; Thavasu, P.; Bakwill, F.; Caponigro, F.; Graf, P.; Dutreix, C; Blakie, R.; Kaye, S.B.; Gane-san, T.S.; Talbot, D.C.; Harris, D.L.; Twelves, C. Phase I and pharmacokineticstudy of PKC412, an inhibitor of protein kinase C. J. Clin. Oncol, 2001, 19, 1485-1492.
33. Peter, A. Campochiaro1 and The C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest. Ophthalmol. Vis. Sci., 2004, 45, 922-931.
34. Ishii, H.; Jirousek, M.; Koya, D.; Takagi, C; Xia, P.; Clermont, A.; Bursell, S.E.; Kern, T.S.; Ballas, L.M.; Heath, W.F.; Stramm, L.E.; Feener, E.P.; King, G.L. Amelioration of vascular dysfunction in diabetic rats by an oral PKCb inhibitor. Science, 1996, 272, 728-731.
35. Jirousek, M.R.; Gillig, J.R.; Gonzalez, CM.; Heath, W.F.; McDonald, J.H.; Neel, D.A.; Rito, C.J.; Singh, U.; Stramm, L.E.; Melikian-Badalian, A.; Baevsky, M.; Ballas, L.M.; Hall, S.E.; Winneroski, L.L.; Faul, M.M. (s)-13-[(dimthylamino)methyl]-10,11,14,15-tetrahydro-4,9,16,21-dimetheno-1H,13H dibenzo [e,k] pyrrolo [3,4] [1,4,13] oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues, isozyme selective inhibitors of protein kinase C beta. J. Med. Chem., 1996, 39, 2664-2671.
36. Das Excimen, N.; King, G.L. The role of protein Kinase C activation and the vascular complications of diabetes. Pharmacol. Res., 2007, 55 (6), 498-510.
37. Kelly, D. J.; Zhang, Y.; Hepper, C; Gow, R.M.; Jaworski, K.; Kemp, B.E.; Wilkinson-Berka, J.L.; Golbert, R. E. Protein kinase C (3 inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003, 52, 512-518.
38. Aiello, L. P.; Bursell, S.E.; Devries, T.; Alatorre, C; King, G. L.; Ways, D.K. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes- induced retinal hemodynamic abnormalities in patients. Invest. Ophthalmol. Vis. Sci., 2006, 47, 86-92.
39. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy, initial results of the PKC-DRS multicen-ter randomized clinical trial. Diabetes, 2005, 54, 2188-2197.
40. Gardner, T.W.; Antonetti, D.A. Ruboxistaurin for diabetic retinopathy. Ophthalmology, 2006, 113, 2135-2136.
41. PKC-DRS2 Study Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology, 2006, 113, 2221-2230.
42. Strom, C; Sander, B.; Klemp, K.; Aiello, L.P.; Lund-Andersen, H.; Larsen, M. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest. Ophthalmol. Vis. Sci., 2005, 46, 3855-3858.
43. PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema, thirty-month results of the randomized. PKC-DMES clinical trial. Arch. Ophthalmol, 2007, 125 (3), 318-324.
44. Dawis, M.D.; Sheetz, M.J.; Aiello, L.L.P.; Milton, R.C.; Danis, R.P.; Aniz, X.Z.; Jiménez, M.C. Vignati L for the PKC DRS2 Study Group. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest. Ophthalmol. Vis. Sci., 2009, 50, 1-4.